Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Story continues below

Departure of Directors or Certain Officers

On March 21, 2019, Susan Wiviott, J.D.,notified Kadmon Holdings, Inc. (the “Company”) of her intent to not stand for re-election as a member of the Board of Directors of the Company (the “Board”). Ms. Wiviott will serve out her remaining term but will resign from the Board and its committees effective as of the date of the Company’s 2019 annual meeting of shareholders (the “Annual Meeting”) to be held on May 15, 2019. Ms. Wiviott serves as a member of the Compensation Committee of the Board and as a member of the Nominating and Corporate Governance Committee of the Board. Ms. Wiviott confirmed that her intent not to stand for re-election was not the result of any disagreement with the Company. The Company thanks her for her service and wishes her well in her future endeavors.

Item 5.02

Regulation FD Disclosure

On March 22, 2019, the Company issued a press release announcingMs. Wiviott’s intent not to stand for re-election as a member of the Board at the upcoming Annual Meeting to be held on May 15, 2019.

The information in this Item 5.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18 of the Exchange Act. The information in this Item 5.02 shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, or into any filing or other document to the Exchange Act, except as otherwise expressly stated in any such filing.

The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 5.02

Financial Statements and Exhibits.

(d) Exhibits

Kadmon Holdings, Inc. Exhibit
EX-99.1 2 kdmn-20190322xex99_1.htm EX-99.1 99.1 Board Member Resignation   Exhibit 99.1  Kadmon Announces Susan Wiviott to Step Down from Board of Directors  NEW YORK,…
To view the full exhibit click here

About Kadmon Holdings, Inc. (NYSE:KDMN)

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

An ad to help with our costs